Opko Health Inc. (OPK) is a publicly traded Healthcare sector company. As of May 21, 2026, OPK trades at $1.20 with a market cap of $853.25M and a P/E ratio of -4.50. OPK moved +7.83% today. Year to date, OPK is -3.91%; over the trailing twelve months it is -7.52%. Its 52-week range spans $0.98 to $2.04. Analyst consensus is strong buy with an average price target of $3.00. Rallies surfaces OPK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ModeX to Reveal MDX3001 In Vivo CAR-T Generation and Deep B-Cell Depletion Data: OPKO Health's ModeX will present preclinical data showing its MDX3001 LNP/mRNA candidate generates CAR-T cells in vivo and achieves deep B-cell depletion in blood, spleen, bone marrow and lymph nodes in humanized mouse and non-human primate models. The CD3xCD28 antibody-conjugated LNP platform obviates ex vivo manufacturing and chemotherapy preconditioning.
| Metric | Value |
|---|---|
| Price | $1.20 |
| Market Cap | $853.25M |
| P/E Ratio | -4.50 |
| EPS | $-0.27 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.04 |
| 52-Week Low | $0.98 |
| Volume | 132 |
| Avg Volume | 0 |
| Revenue (TTM) | $581.12M |
| Net Income | $-212.91M |
| Gross Margin | 35.98% |
4 analysts cover OPK: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $3.00.